top of page
CPMEA EN_FR.png

Building Canada Strong: Making Pharmaceutical Manufacturing a National Priority

Writer: CPMEA
CPMEA
11 minutes ago
5 min read

Canada's pharmaceutical manufacturing sector is at an important turning point. As global trade relationships shift and countries increasingly prioritize domestic production, the policies governments put in place today will play a significant role in determining where medicines are manufactured, where companies invest, and where jobs are created.

 

For Canada, the opportunity is clear. We already have an established pharmaceutical manufacturing sector, supported by skilled workers, modern facilities, and Canadian generic and contract manufacturers. What we need now is an industrial policy framework that builds on these strengths and positions Canada for long-term growth.

 

Prime Minister Mark Carney's recent announcement of The Plan for a Stronger Canada represents an important step in this direction.


Pharmaceutical Manufacturing as a Strategic National Priority

On October 29, 2026, Prime Minister Carney announced The Plan for a Stronger Canada, a new national security strategy focused on strengthening Canadian sovereignty, economic resilience, and domestic industrial capacity.

 

Importantly, the plan identifies pharmaceuticals and biotechnology among eight strategic capabilities essential to Canada's national resilience.

 

The strategy also recognizes the need to safeguard access to essential medicines by strengthening biomanufacturing capacity, modernizing regulations, and securing critical healthcare supply chains.

 

This recognition is significant. It reinforces a message that the Canadian Pharmaceutical Manufacturers and Exporters Alliance (CPMEA) has consistently advocated: pharmaceutical manufacturing is not simply another industry. It is a strategic national asset that supports Canada's healthcare system, economy, and security.

 

Recognizing the sector's importance is a positive step. The next challenge is ensuring that this recognition translates into policies that support the Canadian manufacturers already producing medicines here at home.


Manufacturing Investment Follows Policy

Pharmaceutical manufacturing requires substantial investment, specialized facilities, skilled workers, and long-term planning. Companies making decisions about where to establish or expand production must consider a wide range of factors, including regulatory requirements, operating costs, taxation, procurement practices, and access to markets.

 

These decisions are increasingly influenced by industrial policies.

 

Around the world, governments are taking a more active role in supporting strategically important industries. The United States, for example, has introduced trade measures and policies intended to encourage pharmaceutical manufacturing within its borders.

 

As countries compete to attract and retain investment, Canada must ensure that its own policy environment remains competitive.

 

Manufacturers need predictability. They need confidence that investments made today will remain viable in the years ahead. They also need a government that recognizes domestic pharmaceutical production as an important part of Canada's economic and healthcare infrastructure.

 

Strong industrial policy can help create those conditions.

 

Using Procurement to Strengthen Canadian Manufacturing

One of the most important tools available to governments is public procurement.

 

Every year, governments and publicly funded healthcare systems purchase significant quantities of pharmaceutical products. These purchasing decisions have implications that extend beyond the immediate cost of medicines.

 

Procurement policies can help determine where products are manufactured, where businesses invest, and whether domestic production remains commercially viable.

 

A Canada-first procurement approach that gives appropriate consideration to medicines manufactured by Canadian companies could help strengthen domestic production while supporting long-term investment in the sector.

 

This does not mean turning away from international trade. Canada will continue to benefit from strong relationships with reliable trading partners. However, procurement policy should also recognize the strategic value of maintaining pharmaceutical manufacturing capacity within our own borders.

 

Prime Minister Carney's new plan identifies the implementation of a Buy Canadian Policy as part of strengthening Canada's economic security.

 

For CPMEA, this presents an important opportunity to ensure that Canadian generic and contract pharmaceutical manufacturers are included in the broader conversation about domestic procurement and industrial development.

 

Creating the Conditions for Long-Term Investment

Procurement is only one part of a successful industrial strategy.

 

Canada also needs a regulatory environment that is efficient, predictable, and supportive of domestic manufacturers.

 

Earlier this year, Health Canada announced a pilot initiative to prioritize the review of generic drug submissions from Canadian producers. This was an encouraging step that demonstrated the government's willingness to recognize the importance of domestic pharmaceutical manufacturing.

 

Building on this progress through greater regulatory predictability and alignment with trusted international partners could further strengthen Canada's competitiveness.

 

Competitive tax policies are equally important. Pharmaceutical manufacturers make significant capital investments in facilities, equipment, and production capabilities. Refundable tax credits and other targeted measures could help encourage companies to establish, maintain, and expand production in Canada.

 

Together, these policies can help create an environment where Canadian manufacturers have the confidence to make long-term commitments.

 

Building on Canada's Existing Strengths

Canada is not starting from scratch.

 

Canadian generic and contract manufacturers already play an essential role in supplying medicines, supporting skilled employment, and contributing to the national economy.

 

The challenge is ensuring that this foundation is not weakened as international competition for manufacturing investment intensifies.

 

Industrial policy should not focus exclusively on attracting new facilities or emerging industries. It must also support the established manufacturers that have invested in Canada, developed specialized expertise, and built the production capabilities our healthcare system depends upon.

 

Maintaining and expanding this capacity is essential to achieving greater pharmaceutical self-sufficiency.

 

Canada's industrial strategy should recognize that retaining existing manufacturing is just as important as attracting new investment.

 

Turning Recognition Into Action

Prime Minister Carney's Plan for a Stronger Canada provides an important opportunity to position pharmaceutical manufacturing within Canada's broader economic and national security priorities.

 

The recognition of pharmaceuticals as a strategic capability is welcome. However, achieving the plan's objectives will require coordinated action and policies that address the practical realities facing domestic manufacturers.

 

CPMEA's Five-Point Action Plan provides a framework for moving forward, including Canada-first procurement, priority regulatory review, competitive tax measures, stronger regulatory alignment, and strategic approaches to securing Canada's medicine supply.

 

These recommendations are designed to strengthen the manufacturers already operating in Canada while creating conditions that encourage continued investment and growth.

 

As the federal government advances its new national security strategy, Canadian generic and contract manufacturers must have a meaningful role in shaping the policies that will determine the sector's future.

 

Building Canada's Pharmaceutical Future

The global pharmaceutical landscape is changing, and Canada has an opportunity to respond with a clear, long-term industrial strategy.

 

A strong pharmaceutical manufacturing sector supports more than healthcare. It strengthens our economy, creates skilled jobs, supports Canadian communities, and gives our country greater control over its supply of essential medicines.

 

Prime Minister Carney's recent announcement recognizes the importance of building Canada's strategic industrial capabilities. Now is the time to translate that vision into action.

 

By supporting Canadian generic and contract manufacturers through competitive industrial policies, strategic procurement, and long-term investment, Canada can strengthen its pharmaceutical sector and build a more secure, resilient, and self-sufficient future.

 

Building Canada Strong means building the industries Canada depends on. Pharmaceutical manufacturing must be part of that commitment.

 

 
 
bottom of page